Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population). This is because the technology is an option alongside current standard treatment options.

Because aflibercept has been recommended through the fast track appraisal process, NHS England and commissioning groups have committed to providing funding to implement this guidance 30 days after publication.

The list price of aflibercept has a discount that is commercial in confidence. For enquiries about the patient access scheme contact access.team@bayer.com.

The technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.


This page was last updated: 01 November 2017